metaLinear

metaLinear focuses on the identification and validation of new drug targets for difficult to treat bacterial infections.

metaLinear focuses on the identification and validation of new drug targets for difficult to treat bacterial infections. metaLinear uses a proprietary proteome engineering platform technology to uncover, characterise and validate new targets for antibiotics. Using very large libraries of Randomised proteins (R-teins) expressed in target bacteria, metaLinear will screen for novel targets responsible for the desired phenotype. A key advantage of this approach is the ability to de-risk targets and hence provide multiple efficiency gains in the traditional target and drug discovery process.